Personalized Cancer Vaccine Engine NeoVax Released: From Tumor Genome to Vaccine Formula in Just 72 Hours

Personalized Cancer Vaccine Engine NeoVax Released: From Tumor Genome to Vaccine Formula in Just 72 Hours

On March 16, 2029, BioNTech and Microsoft Research jointly released the NeoVax personalized cancer vaccine design platform. The system compresses the entire process from patient tumor genome sequencing to vaccine candidate molecule formulation to 72 hours — an order-of-magnitude improvement over the previous manual design process, which typically took 4 to 6 weeks.

NeoVax's workflow consists of four steps: first, whole-exome sequencing of patient tumor tissue to identify tumor-specific mutations (neoantigens); then an AI model predicts which mutant peptides can be effectively presented by the patient's own MHC molecules; next, the most immunogenic combination is selected from hundreds of candidate peptides; and finally, the mRNA sequence and lipid nanoparticle formulation are optimized.

BioNTech CEO Ugur Sahin said: "The core challenge of personalized cancer vaccines is time. Cancer won't wait while you spend 6 weeks designing a vaccine. NeoVax compresses this to 3 days, making vaccine therapy truly capable of keeping pace with disease progression."

NeoVax's AI model was trained on an immunopeptidomics dataset of 120,000 cancer patients, accumulated by BioNTech over the past 5 years. The model predicts neoantigen binding affinity with over 15,000 known HLA alleles at 92% accuracy.

In a Phase II trial for advanced melanoma, patients treated with NeoVax-designed personalized vaccines combined with PD-1 inhibitors showed a 12-month progression-free survival rate of 58%, compared to 34% for the control group receiving PD-1 inhibitors alone. Similar improvement trends were observed in the NSCLC Phase II trial.

NCI immunotherapy division director James Gulley commented: "NeoVax represents a deep fusion of computational biology and immunotherapy. The 72-hour design cycle is an important milestone, but the real bottleneck for personalized vaccines may be regulatory approval — each patient's vaccine is a unique product, and the existing drug approval framework needs to adapt to this new paradigm."